TY - T1的发生率和临床特点的帕金森病发病率以人群为基础的队列在奥姆斯特德县精神病MN (2006 - 2015)。(S12.008) JF -神首页经学乔-神经学六世- 98 - 18补充SP - 1729 AU -埃Camerucci AU -艾登·马伦AU -格雷琴Ahrens盟又是Turcano AU -科尔刺伤盟詹姆斯·鲍尔AU -布拉德利Boeve盟Rodolfo Savica Y1 - 2022/05/03 UR - //www.ez-admanager.com/content/98/18_Supplement/1729.abstract N2 -目的:定义发病率、临床特征、药物用于帕金森氏症患者的精神病(PDP)。背景:精神病是一种常见症状的帕金森病(PD)和可能影响患者的生活质量。然而,很少有研究调查精神病的发病率在PD在以人群为基础的队列。设计/方法:罗彻斯特流行病学项目是用于定义以人群为基础的事件队列的PD奥姆斯特德县2006 - 2015 MN。运动障碍专家审查所有临床图表确认PD的诊断。被诊断为PDP使用研究所/ NIMH统一标准。结果:225年的PD患者中,69例(31%)病例为PDP符合诊断标准。PDP PD患者发病率为3.51/100人年和精神病发作的平均年龄为79.8岁(IQR: 74.7 - -85.8)。视觉幻觉是最常见的精神功能(72.5%),其次是错觉(26.1%)。精神病是瞬态在PDP 44/69(63.8%)的情况下,持续时间的中位数68天(-388年差:29.5)。 Overall, 45% (31/69) of PDP patients were prescribed an antipsychotic medication. In PDP patients, a similar percent of those with transient psychosis were prescribed antipsychotic medications 20/44 (45%) as those with persistent psychosis 11/25 (42%). This difference was not statistically significant (p= 0.80). Antipsychotic medications included quetiapine (28.6%), olanzapine (4.3%), and haloperidol (4.3%), with a median treatment time of 2.8 years (IQR: 0.3–4.0).Conclusions: The incidence of psychosis in our PD cohort was 3.51 cases per 100 person-years. Visual hallucinations and delusions were the most frequently observed psychotic features.Psychosis symptoms were resolved in almost 2/3 of PDP cases within two months from onset. Overall, 45% of PDP cases were prescribed an antipsychotic medication. The percentage of PDP patients prescribed an antipsychotic was similar between those with transient and persistent psychosis.Disclosure: Dr. Camerucci has nothing to disclose. Aidan Mullan has nothing to disclose. Ms. Ahrens has nothing to disclose. Dr. Turcano has nothing to disclose. Mr. Stang has nothing to disclose. The institution of Dr. Bower has received research support from Abbvie. Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Biogen. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from GE Healthcare. Dr. Boeve has received publishing royalties from a publication relating to health care. The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc. ER -